Cyclops MedTech: Financial Breakdown
Decoding financial health metrics of Cyclops MedTech
Total Revenue₹4.9 Cr19%Prev. FY
Total Expenses₹4.8 Cr32%Prev. FY
Profit After Tax₹13.7 Lakh-82%Prev. FY
Total Assets₹6.7 Cr12%Prev. FY
Net Profit Margin2.8%-85%Prev. FY
FAQs on Financials of Cyclops MedTech
Yes. In FY23, Cyclops MedTech reported a profit after tax of ₹13.7 Lakh, making it profitable.
Cyclops MedTech's revenue grew 19.3% year-on-year, from ₹4.1 Cr in FY22 to ₹4.9 Cr in FY23.
Cyclops MedTech's estimated EBITDA for FY23 was ₹37.3 Lakh, derived from its profit before tax, finance costs, and depreciation & amortisation.
In FY23, Cyclops MedTech posted revenue of ₹4.9 Cr (up 19.3% YoY) and a profit after tax of ₹13.7 Lakh. Explore the full financials of Cyclops MedTech here...
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links